Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05424692

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Colon Cancer Chemotherapy Effect Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Exon Mutation Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site PTC Rectal Cancer Rectal Diseases Rectal Neoplasms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The study is a multi agency prospective cohort study in China. The subjects were patients aged 18 ~ 75 years with colorectal cancer diagnosed by histopathology or cytology. They must be colorectal cancer patients who have at least one assessable tumor focus, need adjuvant therapy after radical surgery, and have not received neoadjuvant therapy， ECoG physical condition score ≤ 2 points. And they must be voluntarily participate in and sign informed consent.

The patients were randomly divided into PTC drug sensitivity test group and control group. The PTC drug sensitivity test group selected the adjuvant chemotherapy scheme according to the 3D drug sensitivity test results of micro tumor (PTC) in vitro. The control group made adjuvant chemotherapy strategy according to clinical experience. All exon (WES) data collection was used to predict postoperative survival in both groups.

The primary endpoint was the non inferiority test, and the 3-year disease-free survival rate was T-C >- Δ

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 ~ 75 years old, regardless of gender
  • Patients with colorectal cancer diagnosed by histopathology or cytology
  • Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy
  • Having at least one assessable tumor focus
  • ECoG physical condition score ≤ 2 points
  • Voluntarily participate and sign informed consent

Exclusion criteria

  • Patients diagnosed with metastasis
  • Patients who cannot obtain tumor samples
  • Pregnant and lactating women
  • Patients with poor compliance
  • Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment
  • Patients with other malignant tumors
  • Suffering from serious mental and nervous system diseases
  • The researchers believe that patients should not be selected for this study

Treatment and study plan

5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate

Drug

Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.

Other names: PTC drug sensitivity results

Primary outcomes

  1. The difference of 3-year disease-free survival rate of patients in both group

    Time frame: 3 years

    Follow-up the survival status of patients, and calculate 3-year disease-free survival rate of patients in both group

Secondary outcomes

  1. The relation between TMB and clinical outcomes

    Time frame: 3 years

    Use tumor whole exon (WES) sequencing to detect the Tumor Mutation Burden (TMB) of patients, and use correlation analysis to detect whether it's risk factor of clinical outcomes.

  2. The relation between MSI and clinical outcomes

    Time frame: 3 years

    Use tumor whole exon (WES) sequencing to detect the Microsatellite Instability (MSI) of patients, and use correlation analysis to detect whether it's risk factor of clinical outcomes.

  3. The relation between dMMR and clinical outcomes

    Time frame: 3 years

    Use tumor whole exon (WES) sequencing to detect the Deficient Mismatch Repair (dMMR) of patients, and use correlation analysis to detect whether it's risk factor of clinical outcomes.

  4. The difference of clinical outcomes of patients in both group

    Time frame: 3 years

    Follow-up the health status and weather tumor recurrence and metastasis of patients, and evaluate whether the test results of extended drug regimen correspond with clinical outcomes

  5. The difference of TTP of patients in both group

    Time frame: 3 years

    Follow-up the results of patients' periodic reviews and calculate Time To Progress (TTP） of patients in both group, and use survival analysis to detect whether the two group has difference in TTP.

  6. The difference of ORR of patients in both group

    Time frame: three years

    Follow-up the results of patients' periodic reviews and calculate Objective Response Rate (ORR） of patients in both group, and use survival analysis to detect whether the two group has difference in ORR.

  7. The difference of DFS of patients in both group

    Time frame: 3 years

    Follow-up the results of patients' periodic reviews and calculate Disease Free Survival (DFS) of patients in both group, and use survival analysis to detect whether the two group has difference in DFS.

  8. The difference of PFS of patients in both group

    Time frame: 3 years

    Follow-up the results of patients' periodic reviews and calculate Progress Free Survival (PFS） of patients in both group, and use survival analysis to detect whether the two group has difference in PFS.

  9. The difference of OS of patients in both group

    Time frame: 3 years

    Follow-up the results of patients' periodic reviews and calculate Overall Survival (OS） of patients in both group, and use survival analysis to detect whether the two group has difference in OS.

Study contacts

Contact information is provided by the study sponsor or research team.

Guole Lin

CONTACT

[email protected]

13801081483

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Registry information

Official study title

Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined with Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer

Important dates

Study start
2021
Primary completion
2025
Study completion
2027
First posted
Jun 21, 2022
Registry last updated
Nov 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.